Global Nausea Medicine Market Research Report—Forecast till 2027

$4,450$6,250

The global Nausea Medicine Market is anticipated to witness a notable CAGR of 7.83% to surpass USD 2423.26 Million by the forecast period of 2027. Nausea medicines are used to treat conditions such as nausea and vomiting.

Clear

Description

Global Nausea Medicine Market Research Report—Forecast till 2027

Market Synopsis

The global Nausea Medicine Market is anticipated to witness a notable CAGR of 7.83% to surpass USD 2423.26 Million by the forecast period of 2027. Nausea medicines are used to treat conditions such as nausea and vomiting. The global market growth is attributed to the rising cases of cancer increase in gastrointestinal diseases, and growing geriatric population, sedentary lifestyle, and unhealthy diet.
The global Nausea Medicine Market is expected to register a healthy market growth during the review period owing to the increasing cases of cancer worldwide. The United States has more patients of cancer patients as per the study of the national cancer Institute approximately 1.8 Million people will be diagnosed with cancer in 2020. In 2017, as per the Cancer Research UK, in females in the UK, there were more than 179,000 new cancer cases and in males in the UK, there were around 187,000 new cancer cases that are likely to propel the market in the future. However, a high preference for home remedies is anticipated to restrain the growth of this market during the review period. Furthermore, collaborations between large drug manufacturing companies and small companies are expected to register the lucrative opportunity for the growth of the global Nausea market during the assessment period.
Market Segmentation
Global Nausea Medicine Market has been classified into Type, Mode of Administration, Indication, and Distribution Channel.
Based on the type, the nausea medicine market has been divided into antagonists, cannabinoids, antihistamines, and others. The nausea medicine market, in terms of the mode of administration category, is classified into oral, intravenous, and others. The nausea medicine market, based on indication, is classified into oncology, gastroesophageal reflux disease (GERD), motion sickness, and others. Based on distribution channels the market has been classified into hospital/retail pharmacies and online.
Based on indication, the oncology segment held the largest share of 39.84% in 2019 because of the rising number of patients experiencing nausea associated with chemotherapeutic drug use.
Regional Analysis
Geographically, Global Nausea Medicine Market has been classified into the Americas, Europe, Asia-Pacific, and the Middle East & Africa.
The Americas is expected to lead the global nausea medicine market during the review period owing to the presence of major manufacturers, increasing awareness about early disease diagnosis, and the increasing prevalence of gastrointestinal diseases.
The European market is expected to register as the second-largest market for nausea medicine. The regional market is attributed to the biopharmaceutical sector, improving economies, high disposable income per individual, and increased healthcare spending market in this region.
The market in Asia-Pacific is anticipated to exhibit substantial market growth during the review period because of growing awareness about diseases, government support to improve the healthcare sector, and increasing geriatric population.
Key Players
The Major Players in the Global Nausea Medicine Market are Novartis AG (Switzerland), Merck & Co., Inc. (US), F. Hoffmann-La Roche Ltd (Switzerland), GlaxoSmithKline PLC (UK), Pfizer Inc. (US), Sanofi S.A. (France), Mylan NV (US), AstraZeneca (UK), Cipla Inc. (India), and others.
COVID 19 Impacts
We are continuously tracking the impact of the COVID-19 pandemic on various industries and verticals within all domains. Our research reports include the same and help you understand the drop and rise, owing to the impact of COVID-19 on the industries. Also, we help you to identify the gap between the demand and supply of your interested market. Moreover, the report helps you with the analysis, amended government regulations, and many other useful insights.

Additional information

Publisher

Geography Covered

Date Published

Pages

Format

Table of Contents

TABLE OF CONTENT
1 EXECUTIVE SUMMARY
1.1 OVERVIEW 14

1.1.1 MARKET SYPNOSIS 14

2 MARKET INTRODUCTION
2.1 DEFINITION 15

2.2 SCOPE OF THE STUDY 15

2.3 RESEARCH OBJECTIVE 15

2.4 MARKET STRUCTURE 15

2.5 ASSUMPTIONS & LIMITATIONS 16

3 RESEARCH METHODOLOGY
3.1 DATA MINING 17

3.2 SECONDARY RESEARCH 18

3.3 PRIMARY RESEARCH 18

3.4 BREAKDOWN OF PRIMARY RESPONDENTS 19

3.5 FORECASTING TECHNIQUES 20

3.6 RESEARCH METHODOLOGY FOR MARKET SIZE ESTIMATION 21

3.6.1 BOTTOM-UP APPROACH 22

3.6.2 TOP-DOWN APPROACH 22

3.7 DATA TRIANGULATION 23

3.8 VALIDATION 23

4 MARKET DYNAMICS
4.1 OVERVIEW 24

4.2 DRIVERS 25

4.2.1 GROWING CASES OF CANCER 25

4.2.2 RISE IN GASTROINTESTINAL DISEASES 25

4.2.3 INCREASING GERIATRIC POPULATION, SEDENTARY LIFESTYLE, AND UNHEALTHY DIET 25

4.3 RESTRAINTS 26

4.3.1 HIGH PREFERENCE FOR HOME REMEDIES 26

4.4 OPPORTUNITIES 27

4.4.1 COLLABORATIONS BETWEEN LARGE DRUG MANUFACTURING COMPANY AND SMALL COMPANIES 27

5 MARKET FACTOR ANALYSIS
5.1 VALUE CHAIN ANALYSIS 28

5.1.1 R&D AND DESIGNING 29

5.1.2 MANUFACTURING 29

5.1.3 DISTRIBUTION & SALES 29

5.1.4 POST-SALES SERVICES 29

5.2 PORTER’S FIVE FORCES MODEL 30

5.2.1 BARGAINING POWER OF SUPPLIERS 31

5.2.2 BARGAINING POWER OF BUYERS 31

5.2.3 THREAT OF NEW ENTRANTS 31

5.2.4 THREAT OF SUBSTITUTES 31

5.2.5 INTENSITY OF RIVALRY 31

6 GLOBAL NAUSEA MEDICINE MARKET, BY TYPE
6.1 OVERVIEW 32

6.2 ANTAGONISTS 33

6.3 ANTIHISTAMINES 33

6.4 CANNABINOIDS 34

6.5 OTHERS 34

7 GLOBAL NAUSEA MEDICINE MARKET, BY MODE OF ADMINISTRATION
7.1 OVERVIEW 35

7.2 INTRAVENOUS 36

7.3 ORAL 36

7.4 TRANSDERMAL 37

8 GLOBAL NAUSEA MEDICINE MARKET, BY INDICATION
8.1 OVERVIEW 38

8.2 ONCOLOGY 39

8.3 GASTROESOPHAGEAL REFLUX DISEASE (GERD) 39

8.4 MOTION SICKNESS AND SEASICKNESS 40

8.5 OTHERS 40

9 GLOBAL NAUSEA MEDICINE MARKET, BY DISTRIBUTION CHANNEL
9.1 OVERVIEW 41

9.2 HOSPITALS PHARMACY/ RETAIL PHARMACY 42

9.3 ONLINE 42

10 GLOBAL NAUSEA MEDICINE MARKET, BY REGION
10.1 OVERVIEW 43

10.2 AMERICAS 44

10.2.1 NORTH AMERICA 46

10.2.1.1 US 48

10.2.1.2 CANADA 49

10.2.2 SOUTH AMERICA 51

10.3 EUROPE 53

10.3.1 WESTERN EUROPE 55

10.3.1.1 GERMANY 57

10.3.1.2 FRANCE 58

10.3.1.3 UK 60

10.3.1.4 ITALY 61

10.3.1.5 SPAIN 62

10.3.1.6 REST OF WESTERN EUROPE 64

10.3.2 EASTERN EUROPE 65

10.4 ASIA-PACIFIC 67

10.4.1 CHINA 69

10.4.2 JAPAN 70

10.4.3 INDIA 72

10.4.4 AUSTRALIA 73

10.4.5 SOUTH KOREA 74

10.4.6 REST OF ASIA-PACIFIC 76

10.5 MIDDLE EAST & AFRICA 78

10.5.1 MIDDLE EAST 80

10.5.2 AFRICA 81

11 COMPETITIVE LANDSCAPE
11.1 OVERVIEW 83

11.2 MAJOR PLAYERS IN THE GLOBAL NAUSEA MEDICINE MARKET 83

11.3 COMPETITIVE BENCHMARKING 84

11.4 COMPETITOR DASHBOARD 85

11.5 KEY DEVELOPMENTS & GROWTH STRATEGIES 85

11.5.1 ACQUISITIONS 85

12 COMPANY PROFILES
12.1 SANOFI S.A. 86

12.1.1 COMPANY OVERVIEW 86

12.1.2 FINANCIAL OVERVIEW 86

12.1.3 PRODUCTS/SERVICES OFFERED 87

12.1.4 KEY DEVELOPMENTS 87

12.1.5 SWOT ANALYSIS 87

12.1.6 KEY STRATEGIES 87

12.2 NOVARTIS AG 88

12.2.1 COMPANY OVERVIEW 88

12.2.2 FINANCIAL OVERVIEW 88

12.2.3 PRODUCTS/SERVICES OFFERED 89

12.2.4 KEY DEVELOPMENTS 89

12.2.5 SWOT ANALYSIS 89

12.2.6 KEY STRATEGIES 89

12.3 MERCK & CO., INC. 90

12.3.1 COMPANY OVERVIEW 90

12.3.2 FINANCIAL OVERVIEW 90

12.3.3 PRODUCTS/SERVICES OFFERED 91

12.3.4 KEY DEVELOPMENTS 91

12.3.5 SWOT ANALYSIS 91

12.3.6 KEY STRATEGIES 91

12.4 GLAXOSMITHKLINE PLC 92

12.4.1 COMPANY OVERVIEW 92

12.4.2 FINANCIAL OVERVIEW 92

12.4.3 PRODUCTS/SERVICES OFFERED 93

12.4.4 KEY DEVELOPMENTS 93

12.4.5 SWOT ANALYSIS 93

12.4.6 KEY STRATEGIES 94

12.5 MYLAN NV 95

12.5.1 COMPANY OVERVIEW 95

12.5.2 FINANCIAL OVERVIEW 95

12.5.3 PRODUCTS/SERVICES OFFERED 96

12.5.4 KEY DEVELOPMENTS 96

12.5.5 SWOT ANALYSIS 96

12.5.6 KEY STRATEGIES 96

12.6 PFIZER INC. 97

12.6.1 COMPANY OVERVIEW 97

12.6.2 FINANCIAL OVERVIEW 97

12.6.3 PRODUCTS/SERVICES OFFERED 98

12.6.4 KEY DEVELOPMENTS 98

12.6.5 SWOT ANALYSIS 98

12.6.6 KEY STRATEGIES 98

12.7 F. HOFFMANN-LA ROCHE LTD 99

12.7.1 COMPANY OVERVIEW 99

12.7.2 FINANCIAL OVERVIEW 99

12.7.3 PRODUCTS/SERVICES OFFERED 100

12.7.4 KEY DEVELOPMENTS 100

12.7.5 SWOT ANALYSIS 100

12.7.6 KEY STRATEGIES 100

12.8 ASTRAZENECA 101

12.8.1 COMPANY OVERVIEW 101

12.8.2 FINANCIAL OVERVIEW 101

12.8.3 PRODUCTS/SERVICES OFFERED 102

12.8.4 KEY DEVELOPMENTS 102

12.8.5 SWOT ANALYSIS 102

12.8.6 KEY STRATEGIES 102

12.9 CIPLA INC. 103

12.9.1 COMPANY OVERVIEW 103

12.9.2 FINANCIAL OVERVIEW 103

12.9.3 PRODUCTS/SERVICES OFFERED 104

12.9.4 KEY DEVELOPMENTS 104

12.9.5 SWOT ANALYSIS 104

12.9.6 KEY STRATEGIES 104

13 APPENDIX
13.1 REFERENCES 105

13.2 RELATED REPORTS 105